Table 1 Articles included in the clinical overview; they have been divided into 4 thematic areas based on 4 research questions: 1. role of illness awareness; 2. role of patients’ willingness; 3. role of psychopathological factors 4. therapist’s role
From: Resistance to treatment and change in anorexia nervosa: a clinical overview
Thematic area | Number of articles | Authors | Number of patients | Diagnoses | Type of study |
|---|---|---|---|---|---|
Denial versus insight of illness | 7 | Couturier & Lock, [25] | 86 | AN | Retrospective cohort |
Gothelf et al., [26] | 281 | 37 AN;163 other psychiatric disorders; 81 HC | Cross sectional | ||
Konstantakopoulos et al., [27] | 75 | 25 AN; 15 BN; 35 HC | Cross sectional | ||
Konstantakopoulos et al., [28] | 72 | 39 AN; 33 BN | Cross sectional | ||
Schoen et al., [29] | 14 | AN; BN (no subgroups) | Retrospective cohort | ||
Steinglass et al., [30] | 25 | AN | Cross sectional | ||
Viglione et al., [31] | 38 | AN | Cross sectional | ||
Motivation to change | 33 | Ametller et al., [32] | 70 | AN | Prospective cohort |
Ben Tovim et al., [33] | 220 | 95 AN; 88 BN; 37 EDNOS | Longitudinal cohort | ||
Bewell et al., [34] | 127 | AN | Prospective cohort | ||
Burket & Hodgin, [35] | 72 | 49 BN; 11 ANBP; 6 EDNOS; 6 ANR | Retrospective cohort | ||
Carter et al., [36] | 100 | AN | Prospective cohort | ||
Casasnovas et al., [37] | 218 | 58 AN; 95 BN; 65 EDNOS | Cross sectional | ||
Cavedini et al., [38] | 38 | AN | Prospective cohort | ||
Clausen, [39] | 78 | 35 AN; 30 BN; 13 EDNOS | Prospective cohort | ||
Danner et al., [40] | 16 | AN | Cross sectional | ||
Darcy et al., [41] | 20 | AN | Cross sectional | ||
Gale et al., [42] | 202 | 62 BN; 140 AN | Cross sectional | ||
Geller et al., [43] | 99 | 15 ANBP ; 32 ANR ; 41 ANST; 7 BN; 4 BNST | Test validation | ||
Geller et al., [44] | 63 | 24 ANR; 12 ANBP; 21 ANST; 7 BN | Prospective cohort | ||
Geller et al., [45] | 128 | 10 ANR; 9 ANBP; 46 BN; 61 EDNOS | Longitudinal cohort | ||
Herzog et al., [46] | 246 | 61 AN; 95 BN; 90 EDNOS | Prospective cohort | ||
Karlsson et al., [47] | 89 | AN | Prospective cohort | ||
Konstantakopoulos et al., [28] | 72 | 39 AN; 33 BN | Cross sectional | ||
Lund et al., [48] | 79 | AN | Prospective cohort | ||
McHugh et al., [49] | 65 | AN | Prospective cohort | ||
Mewes et al., [50] | 100 | AN | Prospective cohort | ||
Muñoz et al., [51] | 385 | 61 AN; 47 BN; 245 EDNOS | Prospective cohort | ||
Nordbø et al., [20] | 18 | AN | Cross sectional | ||
Nordbø et al., [52] | 18 | AN | Cross sectional | ||
Nordbø et al., [53] | 36 | AN | Cross sectional | ||
Ricca et al., [54] | 103 | 53 AN; 50 ANST | Prospective cohort | ||
Rieger et al., [55] | 44 | AN | Test validation | ||
Salbach-Andrae et al., [56] | 57 | AN | Prospective cohort | ||
Schebendach et al., [57] | 47 | AN recovered | Prospective cohort | ||
Steinglass et al., [30] | 25 | AN | Cross sectional | ||
Touyz et al., [58] | Debate article | ||||
Treasure et al., [59] | Debate article | ||||
Wade et al., [60] | 47 | AN | Prospective cohort | ||
Ward et al., [61] | 35 | 22 ANR; 11 ANBP; 2 BN | Cross sectional | ||
Maintaining factors and treatment outcome | 22 | Castro et al., [62] | 158 | AN | Prospective cohort |
Clausen, [39] | 78 | 35 AN; 30 BN; 13 EDNOS | Prospective cohort | ||
Danielsen & Rø, [63] | 50 | 30 AN; 9 BN; 11 EDNOS | Prospective cohort | ||
Deter et al., [64] | 81 | AN | Prospective cohort | ||
Fairburn et al., [65] | Debate article | ||||
Fassino et al., [66] | 40 | AN | Prospective cohort | ||
Fassino et al., [67] | 42 | AN | Prospective cohort | ||
Fassino et al., [68] | 57 | 28 AN; 29 BN | Prospective cohort | ||
Federici & Kaplan, [69] | 15 | AN | Cross sectional | ||
Fichter et al., [18] | 103 | AN | Prospective cohort | ||
Geller et al., [70] | Debate article | ||||
Goddard et al., [71] | 74 | 63 AN; 7 BN; 4 EDNOS | Prospective cohort | ||
Helverskov et al., [72] | 312 | 58 AN; 68 EDNOS-AN; 111 BN; 75 EDNOS-BN | Prospective cohort | ||
Hjern et al., [73] | 748 | AN | Prospective cohort | ||
Löwe et al., [74] | 84 | AN | Prospective cohort | ||
Salbach-Andrae et al., [56] | 57 | AN | Prospective cohort | ||
Schmidt & Treasure, [75] | Debate article | ||||
Signorini et al., [76] | 58 | AN | Prospective cohort | ||
Steinhausen et al., [77] | 60 | 48 ANR; 6 ANBP; 5 Atypical AN; 1 BN | Prospective cohort | ||
Sutandar-Pinnock et al., [78] | 73 | AN | Prospective cohort | ||
Treasure & Russell., [10] | Debate article | ||||
Vrabel et al., [79] | 74 | 13 AN; 37 BN; 24 EDNOS | Prospective cohort | ||
Therapeutic relationship, countertransference, management of treatment resistance | 18 | Carter et al., [36] | 100 | AN | Prospective cohort |
Darcy et al., [41] | 20 | AN | Cross sectional | ||
Federici & Kaplan, [69] | 15 | AN | Cross sectional | ||
Feld et al., [80] | 19 | 8ANR; 4ANBP; 4 BN; 3 EDNOS | Prospective cohort | ||
Forget et al., [81] | Debate article | ||||
Geller et al., [82] | 181 | Cases: 3 ANBP; 4 ANR; 22 BN; 28 EDNOS | RCT | ||
Controls:3 ANBP; 4 ANR; 21 BN; 28 EDNOS | |||||
Gulliksen et al., [53] | 38 | AN | Cross sectional | ||
Karlsson et al., [47] | 89 | AN | Prospective cohort | ||
Masson & Sheeshka, [83] | Qualitative interview | ||||
Moyers & Rollnick, [84] | Debate article | ||||
Satir et al., [85] | 120 (HP) | Cross sectional | |||
Skårderud et al., [24] | Debate article | ||||
Strober et al., [86] | Debate article | ||||
Tierney & Fox, [87] | 53 (HP) | Cross sectional | |||
Tozzi et al., [88] | 70 | AN | Cross sectional | ||
Treasure et al., [59] | Debate article | ||||
Vitousek et al., [89] | Debate article | ||||
Warren et al., [90] | 43 (HP) | Cross sectional |